Menumenu
  • slide

    Rapid access to our in-house patient-centric Database Network

  • slide

    An experienced sparring partner for your European healthcare questions

  • slide

    Dedicated to research real-life healthcare for the benefit of patients

  • News

    Cohort profile: the PHARMO Perinatal Research Network

    Congratulations to our colleague @Eline Houben, whose publication "Cohort profile: the PHARMO Perinatal Research Network (PPRN) in the Netherlands: a population-based mother–child linked cohort" has made it into the top 10 most read publications in...

    PHARMO Magazine (August 2021)

    We are proud to offer you our latest edition of the PHARMO Magazine. This edition highlights amongst others our presence at the 37th online ICPE conference, how we contribute to COVID-19 related research, and our current collaborations within the ...

    Wetenschappelijk jaarverslag 2020

    Het jaar 2020 was voor iedereen een bijzonder jaar. Termen als lockdown en quarantaine beheersten ons leven en iedereen ging thuiswerken. Maar de studies en overige activiteiten van het PHARMO Instituut gingen onverminderd door en ondanks het bijzond...

  • Events

  • Vacancy

    DATA MANAGER (LOCATIE UTRECHT)

    DATA MANAGER VOOR WETENSCHAPPELIJK ONDERZOEK IN DE ZORG Het PHARMO Instituut is op zoek naar een data manager ter ondersteuning van de afdeling Onderzoek. Heb je affiniteit met data uit de gezondheidszorg en vind je het leuk om kritisch mee te ...

  • icon

    What we do

    As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  • icon

    What we have

    PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.

Publications

  • Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

    Read more

  • No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

    Read more

  • Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

    Read more

  • The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

    Read more